Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons. By stabilizing hyperexcitable neuronal membranes, it reduces repetitive firing and the spread of epileptic activity, thereby decreasing the frequency and severity of seizures.

The specific dose of Lacosamide Fresenius Kabi is determined by the prescribing clinician based on the patient’s clinical condition, age, weight, renal and hepatic function, and concomitant medications. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Lacosamide is distinct for its selective enhancement of slow sodium channel inactivation, offering a different mechanism compared with traditional sodium channel blockers like carbamazepine. It is often chosen for patients who have not achieved adequate seizure control with other agents, and it has a relatively favorable interaction profile.

Lacosamide Fresenius Kabi should be stored at room temperature, below 25 °C, in its original packaging. Protect the vials from moisture and direct light. Do not freeze. Inspect the solution for particulate matter or discoloration before administration.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting, following aseptic technique and the dosing instructions provided by the prescriber.

Serious risks include cardiac arrhythmias such as atrial fibrillation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts or behaviors, respiratory depression, and rare cases of anaphylaxis. Patients should be monitored for these events, especially during treatment initiation or dose changes.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, uncontrolled arrhythmias, or severe renal or hepatic impairment unless dose adjustments are made.